Plasma lipid levels in Alzheimer's disease patients treated by Donepezil hydrochloride: A cross-sectional study

Archives of Gerontology and Geriatrics

Volumn 38, Issue 1, 2004, Pages 61-68

  Adunsky, Abraham ^a,b   Chesnin, Vladimir ^a   Ravona, Ramit ^a   Harats, Dror ^a,b   Davidson, Michael ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alzheimer disease; Blood lipids; Dementia; Donepezil hydrochloride

Indexed keywords

DONEPEZIL;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; FEMALE; FISHER EXACT TEST; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RANK SUM TEST; SEX RATIO; STATISTICAL ANALYSIS; STUDENT T TEST;

MARTES PENNANTI;

EID: 0242383927     PISSN: 01674943     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.archger.2003.08.002     Document Type: Article

References (28)

1. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, DC.
2. Blauw, G.J., Bollen, E.L., Van Buchem, M.A., Westendorp, G.J., 2001. Dementia at old age: a clinical endpoint of atherosclerotic disease. Eur. Heart J. (Suppl. 3), 16-19.
3. Bonarek M., Barberger-Gateau P., Letenneur L., Deschamps V., Iron A., Dubroca B., Dartigues J.F. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology. 19:2000;141-148.
4. Chandra V., Pandav R. Gene-environment interaction in Alzheimer's disease: a potential role for cholesterol. Neuroepidemiology. 17:1998;225-232.
5. Chapman J.A., Korczyn A.D., Karussis D.M., Michaelson D.M. The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology. 57:2001;1482-1485.
6. Diebold K.G., Michel G., Schweizer J., Diebold-Dorsman R.L. Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders? Pharmacopsychiatry. 31:1998;60-67.
7. Doody R., Geldmacher D., Gordon B., Perdomo C., Pratt R. Open label, multicenter, phase 3 extension study of the safety and efficacy of Donepezil hydrochloride in patients with Alzheimer disease. Arch. Neurol. 58:2002;427-433.
8. Elokdah H., Chai S.Y., Ho D., Sulkowski T. Design and synthesis of tricyclic derivates as high-density lipoprotein cholesterol enhancers. Bioorg. Med. Chem. Lett. 11:2001;339-342.
9. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12:1975;189-198.
10. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin. Chem. 18:1972;499-502.
11. Hofman A., Ott A., Breteler M.M., Bots M.L., Slootr A.J., Van Harskamp F., Van Duijn C.N., Van Broeckhoven C., Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet. 349:1997;151-154.
12. Hosmer, D.W., Lemeshow, S., 1989. In: Applied Logistic Regression. Wiley, New York.
13. Kalaria R.N., Ballard C. Overlap between pathology of Alzheimers disease and vascular dementia. Alzheimer Dis. Assoc. Disord. 9(Suppl. 3):1999;S115-S123.
14. Kivipelto M., Helkala E.L., Laakso M.P., Hanninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., Nissinen A. Midlife vascular risk factors and Alzheimer disease in later life: longitudinal population based study. Br. Med. J. 16:2001;1447-1451.
15. Marx J. Alzheimer's disease: bad for the heart, bad for the mind? Science. 294:2001;508-509.
16. Mulder M., Terwel D. Possible link between lipid metabolism and cerebral amyloid angiopathy in Alzheimer's disease: a role for high-density lipoproteins? Haemostasis. 28:1998;174-194.
17. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRCCFAS), 2001. Pathological correlates of late onset dementia in a multicentre, community based population in England and Wales. Lancet 357, 169-175.
18. Osser D.N., Najarian D.M., Dufresne R.L. Olanzapine increases weight and serum triglyceride levels. J. Clin. Psychiatry. 60:1999;767-770.
19. Poirier J. Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. J. Psychiatr. Neurosci. 24:1999a;147-153.
20. Poirier J. Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimers disease. Mol. Diagn. 4:1999b;335-341.
21. Rockwood K., Kirkland S., Hogan D.B., MacKnight C., Merry H., Verreault R., Wolfson C., McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. 59:2002;223-227.
22. Saunders A.M. Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J. Neuropathol. Exp. Neurol. 59:2000;751-758.
23. Scott, H.D., Laake, K.M., 2001a. Statins for the reduction of risk of Alzheimer's disease. Cochrane Database Syst. Rev. (3), CD 003160.
24. Scott, H.D., Laake, K., 2001b. Statins for the prevention of Aalzheimers disease. Cochrane Database Syst. Rev. (4), CD 003160.
25. Simons M., Keller P., Dichgans J., Schulz J.B. Cholesterol and Alzheimer's disease: is there a link? Neurology. 57:2001;1089-1093.
26. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. J. Am. Med. Assoc. 277:1997;813-817.
27. Swan G.E., LaRue A., Carmelli D., Reed T.E., Fabsitz R.R. Heritability and bio-behavioral predictors from the National Heart, Lung and Blood Institute Twin Study. Arch. Neurol. 49:1992;476-481.
28. Weiner M.F., Martin-Cook K., Foster B.M., Saine K., Fontaine C.S., Svetlik D.A. Effects of Donepezil hydrochloride on emotional/behavioural symptoms in Alzheimer's disease patients. J. Clin. Psychiatry. 61:2000;487-492.